Loading
Elanco Animal Health Inc Stock: price and insider trades · United States
5 insiders bought €1.3M of shares over the last 90 days, the latest by Kurzius Lawrence Erik, filed 21 Aug 2026.
Insider Decl.
559
Thresholds
n/a
Buy Volume
€15M
83 ops. · all time
Sell Volume
€1B
1 ops. · all time
Who traded when
BuySaleLawrence Erik Kurzius4 buys
Robert M. VanHimbergen2 buys
Hoover R David1 buy
Jeffrey N. Simmons1 buy
Michael J. Harrington1 buy
Paul Herendeen1 buy
+2 other insiders
Since the insiders bought
- -7.8%Entry US$24.42 · Close 21 Oct 2026 US$22.52
- -8.1%Entry US$24.50 · Close 21 Oct 2026 US$22.52
- -4.9%Entry US$23.67 · Close 21 Oct 2026 US$22.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Elanco Animal Health Inc Buy (bullish), based on 13 analysts. Average price target: US$30.31.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,308 of 26,248 companies
32.7
score / 100
Value32
Quality33
FCF yld2.5%
Earn yld-2.1%
EV/EBITDA22.6x
ROE-3.0%
Gross mgn55%
Net mgn-4.9%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.55
Analyst consensus
13 analystsBuy
US$24.00Target US$30.31(+34%)US$34.00
Income statement
RevenueUS$4.7B
Gross profitUS$2.6B55% margin
EBITDAUS$676M14% margin
Net income-US$232M-4.0% margin
Valuation
PER (forward)17.5x
P/Book1.7x
Beta1.71
Balance sheet & cash
Market capUS$11.3B
Total debtUS$4B
Free Cash FlowUS$284M
Debt / Equity64%
Profitability & ownership
ROE-3.0%
ROA1.6%
% insiders1.2%
% institutions115.5%
Last declaration on 15 October 2026
Declarations559 total
4,350 shares@ US$23.000.0009% mcap11.6% of flowCommonSEC144:0001969223-26-001074
40,000 shares@ US$23.3980.0082% mcap73.9% of flowCommon StockSEC:0001352090-26-000006:0
Canonical exit: 18 Nov 2026 (T+90)
3,998 shares@ US$23.580.0008% mcap36.4% of flowCommon StockSEC:0002001171-26-000006:0
Canonical exit: 16 Nov 2026 (T+90)
5,000 shares@ US$21.820.0010% mcap29.0% of flowCommon StockSEC:0001566340-26-000006:0
Canonical exit: 10 Nov 2026 (T+90)
10,000 shares@ US$23.6850.0021% mcap57.8% of flowCommon StockSEC:0001374175-26-000005:0
Canonical exit: 5 Nov 2026 (T+90)
4,200 shares@ US$23.07760.0009% mcap15.5% of flowCommon StockSEC:0001724169-26-000037:0
Canonical exit: 5 Nov 2026 (T+90)
15,336 shares@ US$24.640.0034% mcap60.8% of flowCommon StockSEC:0001724169-26-000031:0
4,678 shares0Common StockSEC:0001679166-26-000006:0
12,196 shares0Common StockSEC:0001679166-26-000006:1
20,288 shares@ US$23.1240.0% of flowCommon StockSEC:0001892179-26-000006:1
40,985 shares0Common StockSEC:0001892179-26-000006:0
6,492 shares@ US$24.8838.5% of flowCommon StockSEC:0001752437-26-000004:0
4,738 shares@ US$24.8845.0% of flowCommon StockSEC:0002001171-26-000004:0
8,262 shares@ US$24.8817.4% of flowCommon StockSEC:0001892179-26-000004:0
3,371 shares@ US$24.8829.5% of flowCommon StockSEC:0001809748-26-000004:0
3,433 shares@ US$24.8830.9% of flowCommon StockSEC:0001752439-26-000004:0
4,322 shares@ US$24.8836.5% of flowCommon StockSEC:0001982573-26-000004:0
4,392 shares@ US$24.8817.9% of flowCommon StockSEC:0001916473-26-000012:0
4,695 shares@ US$24.8814.7% of flowCommon StockSEC:0001797894-26-000004:0
1,389 shares@ US$24.8828.5% of flowCommon StockSEC:0001754243-26-000004:0
37,898 shares@ US$24.8815.1% of flowCommon StockSEC:0001479079-26-000013:0
14,205 shares0Common StockSEC:0001982573-26-000002:2
5,209 shares0Common StockSEC:0001754243-26-000002:2
9,470 shares0Common StockSEC:0001797894-26-000002:2
25,360 shares0Common StockSEC:0001892179-26-000002:2
25 of 559 declarations
About Elanco Animal Health Inc
At Elanco Animal Health Inc, purchases are the rule: 83 purchases (77 with an amount) worth EUR 15,261,622, with a median of EUR 105,003, and a single sale, EUR 1,342,484,876, by Aktiengesellschaft Bayer (10% Owner), on December 3, 2020. On September 24, 2018, 11 insiders bought on the same day for EUR 1,487,116.
The three largest purchases are Jeffrey N. Simmons's (President, CEO & Director), EUR 1,822,535 on September 4, 2019 and EUR 1,189,265 on August 12, 2024, and Lawrence Erik Kurzius's (Director), EUR 801,054 on August 20, 2026. Simmons files 49, of which 8 purchases; Todd S. Young files 52, of which 3 purchases, ahead of James M. Meer (Chief Accounting Officer, 45) and, tied, Ramiro Martin Cabral and David S. Kinard (39 each).
Read moreShow less
The company's 559 filings cover trades from September 24, 2018 to October 15, 2026, with 453 grants and 22 filings of another kind. 2021 is the busiest year (82), ahead of 2023 (76) and 2024 and 2025 (72 each). Over the last twelve months: 67 filings, including 9 purchases and no sale. The median delay is 2 days.
For 72 purchases with a stored 90-day result, the median is 0.5% and 51% are positive: stored past results, not a forecast. This US healthcare and pharma company is worth USD 11.7 billion; insiders hold 1.2% of the capital.
